MEA Infectious Disease Therapeutics Market

MEA Infectious Disease Therapeutics Market Size (2023 to 2028)

The size of the Middle East and Africa Infectious Disease Therapeutics Market was worth USD 10.57 Billion in 2023 and estimated to reach 15.43 USD Billion by the end of 2028 registering a CAGR of 7.877% between 2023 to 2028.

Bacteria, fungi, viruses, and parasites are some of the microorganisms causing infectious diseases such as malaria, HIV, tuberculosis, influenza. The MEA Infectious diseases therapeutics market is growing owing to the growing incidence of infectious diseases such as malaria, influenza, and other diseases in the region. Other factors, such as poor hygiene and sanitation in the environment, are driving the market for infectious disease therapeutics to grow.

In addition, the rising awareness about the prevention and management of the spread of infectious disease with the increase in the growth of disposable income in the urban areas further increases the growth of the market. Moreover, the increase in the acceptance of advancement and innovation in the technology and the improving medical and healthcare infrastructure in the region, the rise in the accessibility to new advanced instruments is accelerating the growth of the infectious disease therapeutic market.

Furthermore, the rise in the initiatives and funding from government and non-government organizations in research activities to develop new products is expected to provide lucrative growth opportunities to the market.  The rise in competition between major competitors for market expansion in the area through different market strategies such as new products, collaboration, acquisitions, and mergers will accelerate the growth of the infectious disease therapeutic market. However, the market's development is limited by the expiration of patents for infectious disease drugs and a scarcity of skilled and trained experts to produce effective drugs. Additionally, concerns connected to adverse effects report the findings the medicines are impeding market expansion.

MARKET DRIVERS:

Some of the major factors driving the infectious disease therapeutics market's growth include an increase in the occurrence of infectious diseases, an increase in the use of direct-acting antivirals, an increase in healthcare expenditure, an increase in the geriatric population, a rise in healthcare awareness, and a rise in government funding in developing countries. Market demand is expected to expand as more people accept modern technological advancements in healthcare facilities. Increased disposable income in both developed and emerging countries will assist in outpacing market growth. As people become more aware of diseases and appreciate the benefits of early detection, the infectious disease treatments industry will experience a jump in growth potential. Furthermore, the development of compensation methods that benefit ordinary people is increasing demand in this market.

In addition, a number of government and private organisations fund infectious disease research in order to create effective diagnostic and treatment options. The Bill & Melinda Gates Foundation, for example, provided funding to QuantuMDx Group in November 2016 to help the firm develop and test its CAPTURE-XT pathogen concentration technology and Q-POC molecular
diagnostic platform for low-cost tuberculosis testing. In January 2018, the Global Challenges Research Fund awarded the University of Glasgow-led initiative $1.85 million. (GCRF). In order to aid in the early detection and treatment of infectious diseases, this project will develop novel parasitic disease diagnostics as well as rapid testing in distant areas.

MARKET RESTRAINTS:
The market's expansion is being slowed by a scarcity of skilled individuals capable of producing effective medications. Rapid shifts in economic strategies may have a negative influence on the market for infectious medicines. The availability of alternative methods at a cheaper cost is a challenge for market developers. One of the problems limiting market demand is a lack of information about generic erosion. Lack of understanding regarding treatments for disorders, poor treatment adoption, and lack of funding for certain infectious diseases in some countries are projected to limit the growth of the infectious disease therapeutics market during the forecast period. Furthermore, Africa has a high prevalence of infectious diseases and a low rate of therapeutic penetration. 6.5 million people in the West and Central African region were infected with HIV in 2015, according to AVERT, a global HIV and AIDS organisation based in the United Kingdom, with around 28% of those infected taking antiretroviral therapy.

This research report on the Middle East and Africa Infectious Disease Therapeutics Market has been segmented & sub-segmented into the following categories:

Middle East and Africa Infectious Disease Therapeutics Market - By Mode of Treatment:

• Drugs     
• Vaccines 

Middle East and Africa Infectious Disease Therapeutics Market - By Target Organism:

• Antibacterial     
• Antifungal
• Antiviral 
• Antiparasite     
• Others    

Middle East and Africa Infectious Disease Therapeutics Market - By Infection type:

• Bacterial 
• Viral     
• Fungal   
• Parasitic 
• Others  

Middle East and Africa Infectious Disease Therapeutics Market - By Distribution Channels:

• Hospitals 
• Clinics    
• Others     

Middle East and Africa Infectious Disease Therapeutics Market - By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa is projected to have significant growth in the infectious disease therapeutics market during the forecast period. The market growth is fuelled by the prevalence of infectious diseases such as malaria, HIV, influenza, and other diseases. However, key market players in the region are implementing various strategies for developing advanced products as well as raising awareness among the people regarding infectious diseases about its preventive and management measure are accelerates the market growth. 

UAE is estimated to show growth in the infectious disease therapeutics market in the coming years owing to the increase in the medical and healthcare infrastructure, and growing initiatives and fundings from the government and non-government in the research activities is boosting the market growth.

South Africa is also expected to have lucrative growth in the market. The market growth is fuelled by the increase in the competition between the players for expanding the therapeutic market. In South Africa, near the border areas, malaria transmission is more often in which more than 10 percent of the population are at the risk of contracting the disease in the area. It is due to the presence of efficient mosquitoes in the area and is a reliable high transmission. In the previous year, South Africa had 10,000 to 30,000 cases of malaria. As well as an increase in the prevalence of HIV in South Africa with 7.7 million people with a high prevalence rate of 20.4 percent, further are driving the market growth.

Regional Analysis:
The infectious disease treatments market in the Middle East and Africa is predicted to grow significantly over the forecast period. Malaria, HIV/AIDS, influenza, and other infectious diseases are driving market growth. On the other hand, key market participants in the region are employing a variety of strategies for creating improved goods as well as raising public knowledge about infectious diseases and the preventive and management measures that may be done, which is hastening market expansion. Increased medical and healthcare infrastructure, as well as expanding government and non-government initiatives and financing for research activities, are likely to boost the infectious disease treatments market in the UAE in the next years.

South Africa is likewise likely to benefit from the market's expansion. The increase in competition among competitors for increasing the therapeutic market is fuelling market expansion. Malaria transmission is more common near border areas in South Africa, with more than 10% of the population at risk of contracting the disease in the area. It is a reliable high transmission due to the existence of efficient mosquitoes in the area. South Africa had 10,000 to 30,000 malaria cases the preceding year. Further driving market expansion is an increase in HIV prevalence in South Africa, which now has 7.7 million people with a high prevalence rate of 20.4%.

Key market participants dominating the MEA Infectious disease Therapeutics Market covered in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, AstraZeneca, Auritec Pharmaceuticals, Bayer, Astellas Pharma, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida, Bristol-Myers Squibb and Sanofi.